Vanguard Group Inc. Sells 26,028 Shares of Glaukos Corporation $GKOS

Key Points

• Vanguard Group trimmed its stake by 0.4%, selling 26,028 shares and now holds 6,020,492 shares—about 10.48% of Glaukos valued at roughly $679.8 million.
• Company insiders sold a total of 19,657 shares (~$2.25M) in the last quarter—including CFO Alex Thurman and director Aimee Weisner—bringing insider ownership to 5.80%.
• Glaukos reported a Q1 revenue beat with 41% year-over-year growth and a narrower loss, prompting multiple analyst upgrades and a consensus price target near $138.85 with an overall "Moderate Buy" rating.

Vanguard Group Inc. decreased its holdings in Glaukos Corporation (NYSE:GKOS - Free Report) by 0.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,020,492 shares of the medical instruments supplier's stock after selling 26,028 shares during the quarter. Vanguard Group Inc. owned approximately 10.48% of Glaukos worth $679,774,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. UMB Bank n.a. boosted its position in Glaukos by 102.6% during the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 158 shares during the last quarter. First Horizon Corp boosted its position in Glaukos by 1,715.4% during the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier's stock valued at $27,000 after acquiring an additional 223 shares during the last quarter. REAP Financial Group LLC bought a new stake in Glaukos during the third quarter valued at $40,000. Farther Finance Advisors LLC boosted its position in Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier's stock valued at $46,000 after acquiring an additional 215 shares during the last quarter. Finally, Salomon & Ludwin LLC boosted its position in Glaukos by 111.2% during the fourth quarter. Salomon & Ludwin LLC now owns 454 shares of the medical instruments supplier's stock valued at $51,000 after acquiring an additional 239 shares during the last quarter. Institutional investors own 99.04% of the company's stock.

Insider Activity

In other news, CFO Alex R. Thurman sold 2,511 shares of the company's stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total transaction of $267,321.06. Following the transaction, the chief financial officer owned 41,967 shares in the company, valued at approximately $4,467,806.82. This represents a 5.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Aimee S. Weisner sold 15,000 shares of the company's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $117.38, for a total transaction of $1,760,700.00. Following the transaction, the director owned 18,806 shares in the company, valued at $2,207,448.28. This represents a 44.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 19,657 shares of company stock worth $2,250,060 in the last quarter. Company insiders own 5.80% of the company's stock.

Analyst Upgrades and Downgrades

GKOS has been the topic of a number of research analyst reports. Stifel Nicolaus set a $170.00 price target on shares of Glaukos in a research report on Thursday. William Blair raised shares of Glaukos to a "strong-buy" rating in a research report on Friday, January 30th. Piper Sandler reaffirmed an "overweight" rating and set a $165.00 price target on shares of Glaukos in a research report on Wednesday, January 14th. Wells Fargo & Company upped their price target on shares of Glaukos from $135.00 to $138.00 and gave the company an "overweight" rating in a research report on Thursday. Finally, Needham & Company LLC upped their price target on shares of Glaukos from $127.00 to $136.00 and gave the company a "buy" rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Glaukos has an average rating of "Moderate Buy" and a consensus price target of $138.85.

Glaukos Price Performance

Shares of NYSE GKOS opened at $140.38 on Monday. The firm's 50-day moving average price is $114.02 and its 200-day moving average price is $108.01. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $146.75. The firm has a market capitalization of $8.22 billion, a P/E ratio of -42.80 and a beta of 0.94. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The firm had revenue of $150.57 million for the quarter, compared to analyst estimates of $137.00 million. During the same quarter in the prior year, the business earned ($0.22) earnings per share. The business's quarterly revenue was up 41.2% compared to the same quarter last year. Equities research analysts anticipate that Glaukos Corporation will post -0.6 earnings per share for the current fiscal year.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Q1 results and outlook: Glaukos reported a Q1 revenue beat, 41% year-over-year growth, narrower loss and a raised 2026 revenue outlook — the key fundamental catalyst supporting the stock. Zacks: Q1 Earnings Beat & Raised Outlook
• Positive Sentiment: Analyst upgrades: Multiple firms raised ratings/targets after the quarter — BTIG bumped its target to $141 (buy), Wells Fargo to $138 (overweight), JPMorgan to $140 (overweight) and Needham raised its target — these actions validate the quarter’s strength and support further investor interest. BTIG Research PT Raise
• Neutral Sentiment: Analyst target mix: although several firms raised targets and ratings, many new targets are close to the current price, implying limited near-term upside from those specific forecasts. Wells Fargo PT Raise
• Neutral Sentiment: Market reaction nuance: after the after-hours jump, some intraday profit-taking is common when a stock has run up; elevated volume today suggests active repositioning by traders. OCBJ: After-Hours Move
• Negative Sentiment: Some revised price targets are below the current market price (e.g., Needham and others), which can encourage short-term selling or cap upside until guidance and execution confirm sustained growth. Needham PT Update

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.